LICAMINLIMAB

UNII:	D5ZJ707VIR
Formula:
Preferred Substance Name:	LICAMINLIMAB
GSRS Full Record:	D5ZJ707VIR i

1688648-13-6
ESBA-1622
IMMUNOGLOBULIN SCFV, ANTI-(HOMO SAPIENS TNF (TUMOR NECROSIS FACTOR, TNFSF2, DIF, TNF-ALPHA)), HUMANIZED MONOCLONAL ANTIBODY SINGLE CHAIN; IG SCFV HUMANIZED SINGLE CHAIN (V-KAPPA-VH) (1-254) (V-KAPPA (HOMO SAPIENS IGKV1-5*03 (79.2%) -(IGHD) -IGKJ2*02 (77.8%)) CDR-IMGT (8.3.11) (28-35.53-55.92-102) (1-112)) -21-MER GLYCYL-TETRAKIS(TETRAGLYCYL-SERYL) LINKER (113-133) -(VH (HOMO SAPIENS IGHV3-66*01 (76%) -IGHJ6*01 (92.3%)) CDR-IMGT (8.8.14) (159-166.184-191.230-243) (134-254)), PRODUCED IN THE BACTERIA ESCHERICHIA COLI (E. COLI), NON-GLYCOSYLATED
IMMUNOGLOBULIN, ANTI-(HUMAN TUMOR NECROSIS FACTOR .ALPHA.)(HUMAN-ORYCTOLAGUS CUNICULUS MONOCLONAL ESBA1622 SCFV FRAGMENT)
LICAMINLIMAB [INN]
LICAMINLIMAB [USAN]
LME636
LME-636
OCS-02
SS2X3Y9DGM

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

LICAMINLIMAB

Synonyms and Mappings

Resources